Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis
暂无分享,去创建一个
[1] E. Bigio,et al. Monoclonal antibodies that target pathological assemblies of Aβ , 2007, Journal of neurochemistry.
[2] Karen L. Price,et al. Cognitive and functional decline and their relationship in patients with mild Alzheimer's dementia. , 2014, Journal of Alzheimer's disease : JAD.
[3] Vinayak P. Dravid,et al. Towards Non-Invasive Diagnostic Imaging of Early-Stage Alzheimer’s Disease , 2014, Nature nanotechnology.
[4] N. Greig,et al. Early intervention with a small molecule inhibitor for tumor nefosis factor-α prevents cognitive deficits in a triple transgenic mouse model of Alzheimer’s disease , 2012, Journal of Neuroinflammation.
[5] K. Zahs,et al. β-Amyloid oligomers in aging and Alzheimer’s disease , 2013, Front. Aging Neurosci..
[6] P. Fraser,et al. Anti-Amyloid-β-Mediated Positron Emission Tomography Imaging in Alzheimer's Disease Mouse Brains , 2012, PloS one.
[7] E. Mandelkow,et al. Aβ Oligomers Cause Localized Ca2+ Elevation, Missorting of Endogenous Tau into Dendrites, Tau Phosphorylation, and Destruction of Microtubules and Spines , 2010, The Journal of Neuroscience.
[8] Nick C Fox,et al. Amyloid, hypometabolism, and cognition in Alzheimer disease , 2007, Neurology.
[9] J. Marcusson,et al. Intracellular localization of amyloid-β peptide in SH-SY5Y neuroblastoma cells. , 2013, Journal of Alzheimer's disease : JAD.
[10] S. Shimohama,et al. Continuation of Exercise Is Necessary to Inhibit High Fat Diet-Induced β-Amyloid Deposition and Memory Deficit in Amyloid Precursor Protein Transgenic Mice , 2013, PloS one.
[11] W. Klein,et al. Brain transit and ameliorative effects of intranasally delivered anti-amyloid-β oligomer antibody in 5XFAD mice. , 2013, Journal of Alzheimer's disease : JAD.
[12] M. Wolff,et al. The Off-rate of Monomers Dissociating from Amyloid-β Protofibrils* , 2013, The Journal of Biological Chemistry.
[13] J. Correia,et al. Specific Soluble Oligomers of Amyloid-β Peptide Undergo Replication and Form Non-fibrillar Aggregates in Interfacial Environments* , 2012, The Journal of Biological Chemistry.
[14] J. Laurén. Cellular prion protein as a therapeutic target in Alzheimer's disease. , 2013, Journal of Alzheimer's disease : JAD.
[15] R. Wetzel,et al. Polymorphism in the intermediates and products of amyloid assembly. , 2007, Current opinion in structural biology.
[16] T. Morgan,et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[17] E. Mufson,et al. Decreased Brain-Derived Neurotrophic Factor Depends on Amyloid Aggregation State in Transgenic Mouse Models of Alzheimer's Disease , 2009, The Journal of Neuroscience.
[18] Zuanning Yuan,et al. Construction of human Fab library and screening of a single-domain antibody of amyloid-beta 42 oligomers , 2013, Neural regeneration research.
[19] M. Maeda,et al. Human prefoldin inhibits amyloid-β (Aβ) fibrillation and contributes to formation of nontoxic Aβ aggregates. , 2013, Biochemistry.
[20] S. Villegas,et al. Early intervention in the 3xTg-AD mice with an amyloid β-antibody fragment ameliorates first hallmarks of Alzheimer disease , 2013, mAbs.
[21] N. Arispe. Architecture of the Alzheimer's A beta P ion channel pore. , 2004, The Journal of membrane biology.
[22] R. Nussinov,et al. Mechanisms for the Insertion of Toxic, Fibril-like β-Amyloid Oligomers into the Membrane. , 2013, Journal of chemical theory and computation.
[23] Thomas Wisniewski,et al. Immunotherapy for Alzheimer's disease. , 2014, Biochemical pharmacology.
[24] D. Selkoe,et al. Resolving controversies on the path to Alzheimer's therapeutics , 2011, Nature Medicine.
[25] T. Montine,et al. Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive Impairment A Pilot Clinical Trial , 2011 .
[26] L. Maffei,et al. Environmental enrichment strengthens corticocortical interactions and reduces amyloid-β oligomers in aged mice , 2013, Front. Aging Neurosci..
[27] F. LaFerla,et al. Chronic neuron-specific tumor necrosis factor-alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTg-AD mice. , 2008, The American journal of pathology.
[28] W. Klein,et al. Alzheimer's-associated Abeta oligomers show altered structure, immunoreactivity and synaptotoxicity with low doses of oleocanthal. , 2009, Toxicology and applied pharmacology.
[29] Ana P Wasilewska-Sampaio,et al. Expression Profile of Rat Hippocampal Neurons Treated with the Neuroprotective Compound 2,4-Dinitrophenol: Up-Regulation of cAMP Signaling Genes , 2009, Neurotoxicity Research.
[30] C. Hölscher,et al. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease , 2014, Neuropharmacology.
[31] C. Finch,et al. Self-assembly of Aβ1-42 into globular neurotoxins , 2003 .
[32] B. Nacmias,et al. Plasma membrane injury depends on bilayer lipid composition in Alzheimer's disease. , 2014, Journal of Alzheimer's disease : JAD.
[33] S. Strittmatter,et al. Amyloid-β induced signaling by cellular prion protein and Fyn kinase in Alzheimer disease , 2013, Prion.
[34] R. Nussinov,et al. Alzheimer's disease: which type of amyloid-preventing drug agents to employ? , 2013, Physical chemistry chemical physics : PCCP.
[35] K. Zahs,et al. Correlation of specific amyloid-β oligomers with tau in cerebrospinal fluid from cognitively normal older adults. , 2013, JAMA neurology.
[36] J. Trojanowski,et al. Targeting Amyloid-β Peptide (Aβ) Oligomers by Passive Immunization with a Conformation-selective Monoclonal Antibody Improves Learning and Memory in Aβ Precursor Protein (APP) Transgenic Mice* , 2006, Journal of Biological Chemistry.
[37] W. Klein,et al. Deleterious Effects of Amyloid β Oligomers Acting as an Extracellular Scaffold for mGluR5 , 2010, Neuron.
[38] C. Finch,et al. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. , 2004, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[39] A. Akaike,et al. Toxicity in rat primary neurons through the cellular oxidative stress induced by the turn formation at positions 22 and 23 of Aβ42. , 2012, ACS chemical neuroscience.
[40] E. Capetillo-Zarate,et al. Intraneuronal β-amyloid accumulation and synapse pathology in Alzheimer’s disease , 2010, Acta Neuropathologica.
[41] Kang Hu,et al. High-Level Neuronal Expression of Aβ1–42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation , 2000, The Journal of Neuroscience.
[42] R. Pacchiana,et al. Do Astrocytes Collaborate with Neurons in Spreading the “Infectious” Aβ and Tau Drivers of Alzheimer’s Disease? , 2015, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.
[43] Carl Frieden,et al. Quantitative analysis of the time course of Aβ oligomerization and subsequent growth steps using tetramethylrhodamine-labeled Aβ , 2013, Proceedings of the National Academy of Sciences.
[44] Kenjiro Ono,et al. Cross‐seeding effects of amyloid β‐protein and α‐synuclein , 2012, Journal of neurochemistry.
[45] W. Klein,et al. Selective neuronal degeneration induced by soluble oligomeric amyloid beta‐protein , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[46] W. Klein,et al. Hypercholesterolemia accelerates intraneuronal accumulation of Aβ oligomers resulting in memory impairment in Alzheimer's disease model mice. , 2012, Life sciences.
[47] E. Capetillo-Zarate,et al. Accumulation of Intraneuronal β-Amyloid 42 Peptides Is Associated with Early Changes in Microtubule-Associated Protein 2 in Neurites and Synapses , 2013, PloS one.
[48] Björn Granseth,et al. Spreading of Neurodegenerative Pathology via Neuron-to-Neuron Transmission of β-Amyloid , 2012, The Journal of Neuroscience.
[49] N. Arispe. Architecture of the Alzheimer’s AβP Ion Channel Pore , 2003, The Journal of Membrane Biology.
[50] L. Mucke,et al. Fyn Kinase Modulates Synaptotoxicity, But Not Aberrant Sprouting, in Human Amyloid Precursor Protein Transgenic Mice , 2004, The Journal of Neuroscience.
[51] D. Teplow,et al. C-terminal turn stability determines assembly differences between Aβ40 and Aβ42. , 2013, Journal of molecular biology.
[52] W. Griffin,et al. Perispinal etanercept: Potential as an Alzheimer therapeutic , 2008, Journal of Neuroinflammation.
[53] D. Steel,et al. Structural evolution and membrane interactions of Alzheimer's amyloid‐beta peptide oligomers: New knowledge from single‐molecule fluorescence studies , 2014, Protein science : a publication of the Protein Society.
[54] L. Lannfelt,et al. Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer’s disease , 2014, Alzheimer's Research & Therapy.
[55] C. Oliveira,et al. Effect of α-Synuclein on Amyloid β-Induced Toxicity: Relevance to Lewy Body Variant of Alzheimer Disease , 2013, Neurochemical Research.
[56] Mikio Shoji,et al. Sortilin is required for toxic action of Aβ oligomers (AβOs): extracellular AβOs trigger apoptosis, and intraneuronal AβOs impair degradation pathways. , 2012, Life sciences.
[57] H. Levine. Alzheimer’s β-peptide oligomer formation at physiologic concentrations , 2004 .
[58] W Blaine Stine,et al. Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. , 2002, Brain research.
[59] Bappaditya Chandra,et al. Significant structural differences between transient amyloid-β oligomers and less-toxic fibrils in regions known to harbor familial Alzheimer's mutations. , 2014, Angewandte Chemie.
[60] E. Masliah,et al. Structural diversity of Alzheimer's disease amyloid-β dimers and their role in oligomerization and fibril formation. , 2014, Journal of Alzheimer's disease : JAD.
[61] Carl W. Cotman,et al. Exercise counteracts declining hippocampal function in aging and Alzheimer's disease , 2013, Neurobiology of Disease.
[62] Jianxiu Wang,et al. Kinetic studies of inhibition of the amyloid beta (1-42) aggregation using a ferrocene-tagged β-sheet breaker peptide. , 2013, Analytical biochemistry.
[63] Lei Gu,et al. Structural Insights into Aβ42 Oligomers Using Site-directed Spin Labeling*♦ , 2013, The Journal of Biological Chemistry.
[64] J. H. Viles,et al. The cellular prion protein traps Alzheimer's Aβ in an oligomeric form and disassembles amyloid fibers , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[65] A. Touhami,et al. Amyloid β peptides modify the expression of antioxidant repair enzymes and a potassium channel in the septohippocampal system , 2013, Neurobiology of Aging.
[66] S. Ferreira,et al. How does brain insulin resistance develop in Alzheimer's disease? , 2014, Alzheimer's & Dementia.
[67] Yifeng Du,et al. Changes in insulin-signaling transduction pathway underlie learning/memory deficits in an Alzheimer’s disease rat model , 2012, Journal of Neural Transmission.
[68] W. Klein. Synaptotoxic amyloid-β oligomers: a molecular basis for the cause, diagnosis, and treatment of Alzheimer's disease? , 2012, Journal of Alzheimer's disease : JAD.
[69] R. Nitsch,et al. Chronic Intranasal Treatment with an Anti-Aβ30-42 scFv Antibody Ameliorates Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease , 2011, PloS one.
[70] G. López,et al. Membrane-mediated neuroprotection by curcumin from amyloid-β-peptide-induced toxicity. , 2013, Langmuir : the ACS journal of surfaces and colloids.
[71] C. Arias,et al. Amyloid-β Protein Modulates Insulin Signaling in Presynaptic Terminals , 2012, Neurochemical Research.
[72] E. McNay,et al. Intrahippocampal administration of amyloid-β(1-42) oligomers acutely impairs spatial working memory, insulin signaling, and hippocampal metabolism. , 2012, Journal of Alzheimer's disease : JAD.
[73] C. Finch,et al. Purification and characterization of brain clusterin. , 1994, Biochemical and biophysical research communications.
[74] C. Finch,et al. Synaptic Targeting by Alzheimer's-Related Amyloid β Oligomers , 2004, The Journal of Neuroscience.
[75] Marie C. Heffern,et al. Synapse-binding subpopulations of Aβ oligomers sensitive to peptide assembly blockers and scFv antibodies. , 2012, ACS chemical neuroscience.
[76] M. Oh,et al. Donepezil inhibits the amyloid-beta oligomer-induced microglial activation in vitro and in vivo. , 2014, Neurotoxicology.
[77] K. Blennow,et al. Evaluating Amyloid-beta Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer's Disease , 2013 .
[78] Miles Miller,et al. Alzheimer's Therapeutics Targeting Amyloid Beta 1–42 Oligomers I: Abeta 42 Oligomer Binding to Specific Neuronal Receptors Is Displaced by Drug Candidates That Improve Cognitive Deficits , 2014, PloS one.
[79] M. Oh,et al. 6-Shogaol, an active constituent of ginger, attenuates neuroinflammation and cognitive deficits in animal models of dementia. , 2014, Biochemical and biophysical research communications.
[80] T. Rosenberry,et al. The Alzheimer's amyloid-β(1-42) peptide forms off-pathway oligomers and fibrils that are distinguished structurally by intermolecular organization. , 2013, Journal of molecular biology.
[81] B. Hyman,et al. Brain interstitial oligomeric amyloid β increases with age and is resistant to clearance from brain in a mouse model of Alzheimer's disease , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[82] C. Luan,et al. Nanoscale Synaptic Membrane Mimetic Allows Unbiased High Throughput Screen That Targets Binding Sites for Alzheimer’s-Associated Aβ Oligomers , 2015, PloS one.
[83] G. Antoni,et al. Specific uptake of an amyloid-β protofibril-binding antibody-tracer in AβPP transgenic mouse brain. , 2013, Journal of Alzheimer's disease : JAD.
[84] C. Mirkin,et al. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[85] W. Klein,et al. Amyloid-β and tau pathology of Alzheimer's disease induced by diabetes in a rabbit animal model. , 2012, Journal of Alzheimer's disease : JAD.
[86] L. Lannfelt,et al. The murine version of BAN2401 (mAb158) selectively reduces amyloid-β protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. , 2014, Journal of Alzheimer's disease : JAD.
[87] D. Munoz,et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers. , 2012, The Journal of clinical investigation.
[88] A. Drzezga,et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[89] D. Eisenberg,et al. Out-of-register β-sheets suggest a pathway to toxic amyloid aggregates , 2012, Proceedings of the National Academy of Sciences.
[90] T. Morgan,et al. Vaccination with soluble Aβ oligomers generates toxicity‐neutralizing antibodies , 2001, Journal of neurochemistry.
[91] Brian J. Wiltgen,et al. Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-b , 2012 .
[92] B. Aggarwal,et al. Curcumin: an orally bioavailable blocker of TNF and other pro‐inflammatory biomarkers , 2013, British journal of pharmacology.
[93] D. Holtzman,et al. Blocking the interaction between apolipoprotein E and Aβ reduces intraneuronal accumulation of Aβ and inhibits synaptic degeneration. , 2013, The American journal of pathology.
[94] M. Gallagher,et al. A specific amyloid-β protein assembly in the brain impairs memory , 2006, Nature.
[95] J. Schnabel. Amyloid: Little proteins, big clues , 2011, Nature.
[96] Michele Vendruscolo,et al. Proliferation of amyloid-β42 aggregates occurs through a secondary nucleation mechanism , 2013, Proceedings of the National Academy of Sciences.
[97] W. Klunk,et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.
[98] J. Legleiter,et al. Specific domains of Aβ facilitate aggregation on and association with lipid bilayers. , 2013, Journal of molecular biology.
[99] Ole A. Andreassen,et al. A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline , 2012, Nature.
[100] C. Olanow,et al. Parkinson's Disease and Alpha Synuclein: Is Parkinson's Disease a Prion‐Like Disorder? , 2013, Movement disorders : official journal of the Movement Disorder Society.
[101] Martina M. Panzenboeck,et al. Poor physical performance and dementia in the oldest old: the 90+ study. , 2013, JAMA neurology.
[102] W. Klein,et al. Amyloid beta oligomers induce impairment of neuronal insulin receptors , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[103] D. Butterfield,et al. Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer’s disease brain contribute to neuronal death , 2002, Neurobiology of Aging.
[104] W. K. Cullen,et al. Alzheimer’s disease Aβ assemblies mediating rapid disruption of synaptic plasticity and memory , 2012, Molecular Brain.
[105] W. Klein,et al. Memantine Rescues Transient Cognitive Impairment Caused by High-Molecular-Weight Aβ Oligomers But Not the Persistent Impairment Induced by Low-Molecular-Weight Oligomers , 2013, The Journal of Neuroscience.
[106] D. Teplow,et al. Amyloid β-protein oligomers and Alzheimer’s disease , 2013, Alzheimer's Research & Therapy.
[107] Carl W. Cotman,et al. Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.
[108] G. Krafft,et al. Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer’s disease immunotherapeutics , 2014, Alzheimer's Research & Therapy.
[109] E. Matsubara,et al. Disease Modifying Therapies for Alzheimer's Disease Targeting Aβ Oligomers: Implications for Therapeutic Mechanisms , 2013, BioMed research international.
[110] J. Herms,et al. Immunotherapy alleviates amyloid-associated synaptic pathology in an Alzheimer’s disease mouse model , 2014, Brain : a journal of neurology.
[111] S. Sorbi,et al. Lipid rafts mediate amyloid-induced calcium dyshomeostasis and oxidative stress in Alzheimer's disease. , 2013, Current Alzheimer research.
[112] W. Klein,et al. The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease , 2011, Neurobiology of Learning and Memory.
[113] W. Rosenblum. Why Alzheimer trials fail: removing soluble oligomeric beta amyloid is essential, inconsistent, and difficult , 2014, Neurobiology of Aging.
[114] Bin Zhang,et al. Distinct α-Synuclein Strains Differentially Promote Tau Inclusions in Neurons , 2013, Cell.
[115] W. K. Cullen,et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.
[116] G. Krafft,et al. The case for soluble Aβ oligomers as a drug target in Alzheimer's disease. , 2013, Trends in pharmacological sciences.
[117] R. Kayed,et al. Amyloid-β Annular Protofibrils Evade Fibrillar Fate in Alzheimer Disease Brain*♦ , 2011, The Journal of Biological Chemistry.
[118] F. LaFerla,et al. Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology , 2009, Neurobiology of Disease.
[119] John W. Gilbert,et al. Cellular Prion Protein Mediates Impairment of Synaptic Plasticity by Amyloid-β Oligomers , 2009, Nature.
[120] D. Munoz,et al. TNF-α mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer's β-amyloid oligomers in mice and monkeys. , 2013, Cell metabolism.
[121] A. Gräslund,et al. In vitro and mechanistic studies of an antiamyloidogenic self-assembled cyclic D,L-α-peptide architecture. , 2013, Journal of the American Chemical Society.
[122] C. Opazo,et al. Inhibition of amyloid beta-induced synaptotoxicity by a pentapeptide derived from the glycine zipper region of the neurotoxic peptide , 2013, Neurobiology of Aging.
[123] D. Selkoe,et al. The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. , 2000, Biochemistry.
[124] Brett Chromy,et al. Soluble oligomers of β amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus , 2002, Brain Research.
[125] Xin Wu,et al. Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model , 2002, Nature Neuroscience.
[126] Gary Look,et al. Alzheimer's Therapeutics Targeting Amyloid Beta 1–42 Oligomers II: Sigma-2/PGRMC1 Receptors Mediate Abeta 42 Oligomer Binding and Synaptotoxicity , 2014, PloS one.
[127] W. Klein,et al. Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. , 2006, The Journal of biological chemistry.
[128] J. Fantini,et al. Mechanism of cholesterol‐assisted oligomeric channel formation by a short Alzheimer β‐amyloid peptide , 2014, Journal of neurochemistry.
[129] D. Teplow,et al. Amyloid β-protein oligomers and Alzheimer's , 2013 .
[130] A. Diaspro,et al. Different effects of Alzheimer's peptide Aβ(1-40) oligomers and fibrils on supported lipid membranes. , 2013, Biophysical chemistry.
[131] R. Mezzenga,et al. Novel mechanistic insight into the molecular basis of amyloid polymorphism and secondary nucleation during amyloid formation. , 2013, Journal of molecular biology.
[132] H. Levine. Alzheimer's beta-peptide oligomer formation at physiologic concentrations. , 2004, Analytical biochemistry.
[133] C. Finch,et al. Self-assembly of Abeta(1-42) into globular neurotoxins. , 2003, Biochemistry.
[134] Alexander K. Buell,et al. The role of stable α-synuclein oligomers in the molecular events underlying amyloid formation. , 2014, Journal of the American Chemical Society.
[135] Dong Jin Kim,et al. Aminostyrylbenzofuran Directly Reduces Oligomeric Amyloid-β and Reverses Cognitive Deficits in Alzheimer Transgenic Mice , 2014, PloS one.
[136] Elizabeth Head,et al. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers , 2007, Molecular Neurodegeneration.
[137] P. Salinas,et al. The Secreted Wnt Antagonist Dickkopf-1 Is Required for Amyloid β-Mediated Synaptic Loss , 2012, The Journal of Neuroscience.
[138] C. Dobson,et al. Single Molecule Characterization of the Interactions between Amyloid-β Peptides and the Membranes of Hippocampal Cells , 2013, Journal of the American Chemical Society.
[139] A. Vortmeyer,et al. Metabotropic Glutamate Receptor 5 Is a Coreceptor for Alzheimer Aβ Oligomer Bound to Cellular Prion Protein , 2013, Neuron.
[140] P. Mcgeer,et al. Selective inhibition of the membrane attack complex of complement by low molecular weight components of the aurin tricarboxylic acid synthetic complex , 2012, Neurobiology of Aging.
[141] W. Klein,et al. Conformation‐dependent single‐chain variable fragment antibodies specifically recognize beta‐amyloid oligomers , 2009, FEBS letters.
[142] T. Wisniewski,et al. Tau-Based Therapeutic Approaches for Alzheimer's Disease - A Mini-Review , 2014, Gerontology.
[143] Kristina D. Micheva,et al. Oligomeric amyloid β associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques , 2009, Proceedings of the National Academy of Sciences.
[144] Shaomin Li,et al. Rosiglitazone prevents amyloid-β oligomer-induced impairment of synapse formation and plasticity via increasing dendrite and spine mitochondrial number. , 2014, Journal of Alzheimer's disease : JAD.
[145] D. Teplow,et al. Gly25-Ser26 amyloid β-protein structural isomorphs produce distinct Aβ42 conformational dynamics and assembly characteristics. , 2014, Journal of molecular biology.
[146] D. Selkoe,et al. Natural oligomers of the amyloid-β protein specifically disrupt cognitive function , 2005, Nature Neuroscience.
[147] Z. Leonenko,et al. Atomic force microscopy to study molecular mechanisms of amyloid fibril formation and toxicity in Alzheimer’s disease , 2014, Drug metabolism reviews.
[148] M. Schachner,et al. Prion protein recruits its neuronal receptor NCAM to lipid rafts to activate p59fyn and to enhance neurite outgrowth , 2005, The Journal of cell biology.
[149] M. Peng,et al. Plasma amyloid-β oligomers and soluble tumor necrosis factor receptors as potential biomarkers of AD. , 2014, Current Alzheimer research.
[150] S. M. de la Monte. Type 3 diabetes is sporadic Alzheimer׳s disease: mini-review. , 2014, European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology.
[151] W. Klein,et al. Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers , 2009, Proceedings of the National Academy of Sciences.
[152] W. Klein,et al. Aβ Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer's Disease , 2007, The Journal of Neuroscience.
[153] H. Levine,et al. Structure–Activity Relationships of Organofluorine Inhibitors of β‐Amyloid Self‐Assembly , 2012, ChemMedChem.
[154] C. Finch,et al. Alzheimer's disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[155] R. Ryan,et al. Impact of apolipoprotein E on Alzheimer's disease. , 2013, Current Alzheimer research.
[156] E. Mufson,et al. Prefibrillar Tau Oligomers in Mild Cognitive Impairment and Alzheimer's Disease , 2013, Neurodegenerative Diseases.
[157] H. Wiśniewski,et al. Non‐Fibrillar β‐Amyloid Protein is Associated with Smooth Muscle Cells of Vessel Walls in Alzheimer Disease , 1994, Journal of neuropathology and experimental neurology.
[158] Lei Chang,et al. Femtomole immunodetection of synthetic and endogenous amyloid-β oligomers and its application to Alzheimer’s disease drug candidate screening , 2007, Journal of Molecular Neuroscience.
[159] R. V. Van Duyne,et al. Detection of a biomarker for Alzheimer's disease from synthetic and clinical samples using a nanoscale optical biosensor. , 2005, Journal of the American Chemical Society.
[160] K. Blennow,et al. Evaluating Amyloid-β Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer’s Disease , 2013, PloS one.
[161] G. Schellenberg,et al. The Arctic AβPP mutation leads to Alzheimer’s disease pathology with highly variable topographic deposition of differentially truncated Aβ , 2013, Acta Neuropathologica Communications.
[162] V. Villemagne,et al. Metals, membranes, and amyloid-β oligomers: key pieces in the Alzheimer's disease puzzle? , 2012, Journal of Alzheimer's disease : JAD.
[163] T. Willnow,et al. Apolipoprotein E receptor pathways in Alzheimer disease , 2014, Wiley interdisciplinary reviews. Systems biology and medicine.
[164] A. Zvirbliene,et al. Antibodies bound to Aβ oligomers potentiate the neurotoxicity of Aβ by activating microglia , 2013, Journal of neurochemistry.
[165] W. Klein,et al. Temporal Profile of Amyloid-β (Aβ) Oligomerization in an in Vivo Model of Alzheimer Disease , 2006, Journal of Biological Chemistry.
[166] A. Zvirbliene,et al. Immunogenic properties of amyloid beta oligomers , 2013, Journal of Biomedical Science.
[167] W. Klein,et al. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. , 2007, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[168] H. Budka,et al. Intracellular processing of disease-associated α-synuclein in the human brain suggests prion-like cell-to-cell spread , 2014, Neurobiology of Disease.
[169] E. Mandelkow,et al. Lost after translation: missorting of Tau protein and consequences for Alzheimer disease , 2014, Trends in Neurosciences.
[170] L. Mucke,et al. Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. , 2012, Cold Spring Harbor perspectives in medicine.
[171] D. Holtzman,et al. Amyloid‐beta oligomerization in Alzheimer dementia versus high‐pathology controls , 2013, Annals of Neurology.
[172] Hans-Ulrich Demuth,et al. Prion-Like Behavior and Tau-dependent Cytotoxicity of Pyroglutamylated β-Amyloid , 2012, Nature.
[173] B. Drukarch,et al. Tissue transglutaminase in Alzheimer's disease: involvement in pathogenesis and its potential as a therapeutic target. , 2014, Journal of Alzheimer's disease : JAD.
[174] David Eisenberg,et al. Atomic View of a Toxic Amyloid Small Oligomer , 2012, Science.
[175] B. Hyman,et al. Alzheimer's disease: synapses gone cold , 2011, Molecular Neurodegeneration.
[176] V. Lee,et al. Seeding of Normal Tau by Pathological Tau Conformers Drives Pathogenesis of Alzheimer-like Tangles* , 2011, The Journal of Biological Chemistry.
[177] E. Bigio,et al. Alzheimer's disease-type neuronal tau hyperphosphorylation induced by Aβ oligomers , 2008, Neurobiology of Aging.
[178] C. Finch,et al. Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum? , 2001, Trends in Neurosciences.
[179] K. Murakami. Conformation-specific antibodies to target amyloid β oligomers and their application to immunotherapy for Alzheimer’s disease , 2014, Bioscience, biotechnology, and biochemistry.
[180] W. Klein,et al. Intracellular Aβ-oligomers and early inflammation in a model of Alzheimer's disease , 2012, Neurobiology of Aging.
[181] Martin Hallbeck,et al. Spreading of amyloid-β peptides via neuritic cell-to-cell transfer is dependent on insufficient cellular clearance , 2014, Neurobiology of Disease.
[182] W. Klein,et al. Cyclic AMP enhancers and Abeta oligomerization blockers as potential therapeutic agents in Alzheimer's disease. , 2007, Current Alzheimer research.
[183] J. Wands,et al. Alzheimer's Disease is Type 3 Diabetes—Evidence Reviewed , 2008, Journal of diabetes science and technology.
[184] R. Kayed,et al. Molecular mechanisms of amyloid oligomers toxicity. , 2012, Journal of Alzheimer's Disease.
[185] S. Maiti,et al. Thermodynamically stable amyloid-β monomers have much lower membrane affinity than the small oligomers , 2013, Front. Physiol..
[186] Michela Gallagher,et al. A specific amyloid-beta protein assembly in the brain impairs memory. , 2006, Nature.
[187] B. Strooper,et al. The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes , 2012, Nature Neuroscience.
[188] S. Monte. Type 3 diabetes is sporadic Alzheimer׳s disease: Mini-review , 2014, European Neuropsychopharmacology.
[189] N. Toni,et al. An Effector-Reduced Anti-β-Amyloid (Aβ) Antibody with Unique Aβ Binding Properties Promotes Neuroprotection and Glial Engulfment of Aβ , 2012, The Journal of Neuroscience.
[190] T. Tabira,et al. Intracellular accumulation of toxic turn amyloid-β is associated with endoplasmic reticulum stress in Alzheimer's disease. , 2013, Current Alzheimer research.
[191] Shaomin Li,et al. Environmental Novelty Activates β2-Adrenergic Signaling to Prevent the Impairment of Hippocampal LTP by Aβ Oligomers , 2013, Neuron.
[192] Peter Riederer,et al. Different effects of soluble and aggregated amyloid β42 on gene/protein expression and enzyme activity involved in insulin and APP pathways , 2012, Journal of Neural Transmission.
[193] R. Kane,et al. Conformational Differences between Two Amyloid β Oligomers of Similar Size and Dissimilar Toxicity* , 2012, The Journal of Biological Chemistry.
[194] Fabiana A. Caetano,et al. Metabotropic glutamate receptors transduce signals for neurite outgrowth after binding of the prion protein to laminili γ1 chain , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[195] C. Dobson,et al. Rare Individual Amyloid-β Oligomers Act on Astrocytes to Initiate Neuronal Damage , 2014, Biochemistry.
[196] J. Trojanowski,et al. Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. , 2006, The Journal of biological chemistry.
[197] L. Guoqing. Immunotherapy for Alzheimers disease , 2006 .
[198] M. Dadlez,et al. Factors influencing compact-extended structure equilibrium in oligomers of aβ1-40 peptide--an ion mobility mass spectrometry study. , 2014, Journal of molecular biology.
[199] D. Sept,et al. Multivariate Analyses of Amyloid-Beta Oligomer Populations Indicate a Connection between Pore Formation and Cytotoxicity , 2012, PloS one.
[200] J. Ringman,et al. Conformation-Dependent Oligomers in Cerebrospinal Fluid of Presymptomatic Familial Alzheimer's Disease Mutation Carriers , 2012, Dementia and Geriatric Cognitive Disorders Extra.
[201] F. Checler,et al. α-Secretase-derived Fragment of Cellular Prion, N1, Protects against Monomeric and Oligomeric Amyloid β (Aβ)-associated Cell Death* , 2011, The Journal of Biological Chemistry.
[202] E. Siemers,et al. Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid &bgr; After a Single Administration of an Amyloid &bgr; Monoclonal Antibody in Subjects With Alzheimer Disease , 2010, Clinical neuropharmacology.
[203] Fusheng Yang,et al. Curcumin Inhibits Formation of Amyloid β Oligomers and Fibrils, Binds Plaques, and Reduces Amyloid in Vivo* , 2005, Journal of Biological Chemistry.
[204] J. Pozueta,et al. Synaptic changes in Alzheimer’s disease and its models , 2013, Neuroscience.
[205] F. LaFerla,et al. Systemic vaccination with anti‐oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg‐AD mice , 2013, Journal of neurochemistry.